360 related articles for article (PubMed ID: 28506596)
1. Advances in medical imaging for the diagnosis and management of common genitourinary cancers.
Bagheri MH; Ahlman MA; Lindenberg L; Turkbey B; Lin J; Cahid Civelek A; Malayeri AA; Agarwal PK; Choyke PL; Folio LR; Apolo AB
Urol Oncol; 2017 Jul; 35(7):473-491. PubMed ID: 28506596
[TBL] [Abstract][Full Text] [Related]
2. PET in genitourinary tract cancers.
Fanti S; Nanni C; Ambrosini V; Gross MD; Rubello D; Farsad M
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):260-71. PubMed ID: 17464269
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
[TBL] [Abstract][Full Text] [Related]
4. Imaging in genitourinary cancer from the urologists' perspective.
Tsakiris P; de la Rosette J
Cancer Imaging; 2007 May; 7(1):84-92. PubMed ID: 17535776
[TBL] [Abstract][Full Text] [Related]
5. Applications of PET/MR Imaging in Urogynecologic and Genitourinary Cancers.
Oldan JD; Shah SN; Rose TL
Magn Reson Imaging Clin N Am; 2017 May; 25(2):335-350. PubMed ID: 28390533
[TBL] [Abstract][Full Text] [Related]
6. Imaging of Extranodal Genitourinary Lymphoma.
Rohena-Quinquilla IR; Lattin GE; Wolfman D
Radiol Clin North Am; 2016 Jul; 54(4):747-64. PubMed ID: 27265606
[TBL] [Abstract][Full Text] [Related]
7. [Why is PET/CT essential in urooncology?].
Borbély K; Géczi L; Kásler M
Magy Onkol; 2013 Dec; 57(4):282-96. PubMed ID: 24353995
[TBL] [Abstract][Full Text] [Related]
8. Role of positron emission tomography in urological oncology.
Rioja J; Rodríguez-Fraile M; Lima-Favaretto R; Rincón-Mayans A; Peñuelas-Sánchez I; Zudaire-Bergera JJ; Parra RO
BJU Int; 2010 Dec; 106(11):1578-93. PubMed ID: 21078036
[TBL] [Abstract][Full Text] [Related]
9. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
10. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
12. Staging of genitourinary cancers. The role of diagnostic imaging.
Friedland GW
Cancer; 1987 Aug; 60(3 Suppl):450-8. PubMed ID: 3297284
[TBL] [Abstract][Full Text] [Related]
13. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
Urso L; Bauckneht M; Albano D; Chondrogiannis S; Grassetto G; Lanfranchi F; Dondi F; Fornarini G; Lazzeri M; Evangelista L
Expert Rev Med Devices; 2024; 21(1-2):55-72. PubMed ID: 38072680
[TBL] [Abstract][Full Text] [Related]
14. [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].
Stattaus J; Bockisch A; Forsting M; Müller SP
Urologe A; 2005 Jun; 44(6):614-24. PubMed ID: 15905989
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Bhaludin BN; Tunariu N; Koh DM; Messiou C; Okines AF; McGrath SE; Ring AE; Parton MM; Sharma B; Gagliardi T; Allen SD; Pope R; Johnston SRD; Downey K
Eur Radiol; 2022 Sep; 32(9):6514-6525. PubMed ID: 35384456
[TBL] [Abstract][Full Text] [Related]
17. [Multiparametric and molecular imaging of breast tumors with MRI and PET/MRI].
Pinker K; Marino MA; Dr Meyer-Baese A; Helbich TH
Radiologe; 2016 Jul; 56(7):612-21. PubMed ID: 27364727
[TBL] [Abstract][Full Text] [Related]
18. Update on advances in molecular PET in urological oncology.
Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
[TBL] [Abstract][Full Text] [Related]
19. Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT.
Sertic M; Kilcoyne A; Catalano OA; Lee SI
Abdom Radiol (NY); 2022 Sep; 47(9):3174-3188. PubMed ID: 34302185
[TBL] [Abstract][Full Text] [Related]
20. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
